New Molecules For Effective And Cheaper Blood Cancer Treatment

Seven identified molecules can adress chronic myelogenous leukemia
Seven identified molecules can adress chronic myelogenous
leukemia. (Image source)
Seven molecules identified by a team of researchers have been shown to be more potent in treating blood cancer than existing drugs. The molecules can address a type of blood cancer called chronic myelogenous leukemia, characterised by uncontrolled growth of white blood corpuscles (WBCs) in the bone marrow leading to imbalance in the total blood cell count in the body.
Using the molecules, the drugs manufactured were shown to arrest the progression of blood cancer by binding the enzymes in the bone marrow that lead to over-production of WBCs.
The findings come at a time when cancer patients have started showing resistance to existing drugs, and the discovery could lead to cheaper treatments as well.
Drugs like ponatinib, imatinib, dasatinib and nilotinib are at present being used to treat blood cancer.
CML accounts for 12% of all cancers. According to the Cancer Patients' Aid Association, almost 800,000 people suffer from this disease in the world.
The team submitted its findings to Nature: Scientific Reports which were accepted and are due for publication this week.